Vaccines for treating SARS infections in cancer patients
AssigneeCity of Hope
InventorsJianhua Yu, Michael A. Caligiuri
Life of this patent
Estimating the term…
Abstract
Provided herein are, inter alia, compositions including recombinant oncolytic herpes simplex viruses that express SARS-CoV spike (S) protein and viral vectors including nucleic acid sequences encoding SARS-CoV S protein. The compositions are useful for eliciting antibodies to SARS-CoV. The compositions are contemplated to be particularly useful for methods of treating and preventing SARS coronavirus infections in cancer patients.
Claims19
A recombinant oncolytic herpes simplex virus comprising a nucleic acid encoding a fusion protein comprising a SARS-CoV-2 spike (S) protein, a herpes simplex virus glycoprotein D transmembrane domain, and a herpes simplex virus glycoprotein D intracellular domain, wherein the recombinant oncolytic herpes simplex virus is a recombinant oncolytic herpes simplex-1 virus.
A recombinant oncolytic herpes simplex virus particle comprising a SARS-CoV spike (S) protein on a surface of the particle.
A fusion protein comprising a SARS-CoV spike (S) protein, a herpes simplex virus glycoprotein D transmembrane domain, and a herpes simplex virus glycoprotein D intracellular domain.
Dependencies are inferred from the claim text.